Exposure to Potential Cytochrome P450 Pharmacokinetic Drug-Drug Interactions Among Osteoarthritis Patients: Incremental Risk of Multiple Prescriptions
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT01177254|
Recruitment Status : Completed
First Posted : August 6, 2010
Last Update Posted : May 1, 2012
NEMA Research, Inc.
Information provided by (Responsible Party):
Joseph Pergolizzi, MD, NEMA Research, Inc.
Using a retrospective analysis of a large commercial claims database and a Medicare database, the investigators evaluated DDEs that have the potential to cause DDIs among chronic low back pain (cLBP) patients on long-term opioid analgesia, which metabolizes through the CYP450 enzyme system, concomitant with other CYP450-metabolized drug(s).
|Condition or disease|
|Chronic Low Back Pain|
|Study Type :||Observational|
|Actual Enrollment :||10000 participants|
|Observational Model:||Case Control|
|Official Title:||Exposure to Potential Cytochrome P450 Pharmacokinetic Drug-Drug Interactions Among Osteoarthritis Patients: Incremental Risk of Multiple Prescriptions|
|Study Start Date :||September 2010|
|Primary Completion Date :||December 2010|
|Study Completion Date :||February 2011|
No Contacts or Locations Provided